Otsuka reports data from Phase III Alzheimer's agitation trial - MSN

Baxter Alzheimer’s Drug Fails to Meet Phase 3 Endpoints

Baxter International Inc's phase 3 clinical trials for its Alzheimer's drug, immunoglobulin (IG), did not achieve its primary goals of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease. The company has decided to discontinue the trials and will analyze the data to determine future steps.

Nicotinamide Fails to Show Clear Benefit in Reducing Tau Proteins in Early Alzheimer's Trial

A Phase 2 clinical trial (NEAT) evaluated nicotinamide's efficacy in early Alzheimer's disease treatment, with results published in *Neurology*.
The study did not demonstrate a clear benefit of nicotinamide in reducing tau proteins, a key biomarker in Alzheimer's disease.

Corcept's ALS drug trial disappoints, but zero deaths in high-dose group - FirstWord Pharma

Anocca submits application to EMA for pancreatic cancer trial

Cassava Sciences' Simufilam Fails to Meet Endpoints in Phase 3 Alzheimer's Trial; Program Discontinued

Cassava Sciences' Phase 3 ReThink-ALZ trial of simufilam in mild-to-moderate Alzheimer's disease did not meet its co-primary endpoints.
The co-primary endpoints were change in cognition and function assessed by ADAS-COG12 and ADCS-ADL scales at week 52.

Patient dies in Neurogene's Phase I/II Rett syndrome trial - MSN

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment - MSN

Abivax enrols first participant in Phase IIb Crohn's disease drug trial - MSN

Athira Pharma's Fosgonimeton Fails to Meet Primary Endpoint in Phase II/III Alzheimer's Trial

Athira Pharma's fosgonimeton did not meet the primary endpoint in the Phase II/III LIFT-AD trial for mild-to-moderate Alzheimer's disease.
The trial failed to show statistically significant improvement in cognition and function compared to placebo after 26 weeks of treatment.

Alder BioPharmaceuticals to Showcase Eptinezumab's Efficacy in Migraine Prevention at AHS Meeting

Alder BioPharmaceuticals announced the presentation of new data from the PROMISE 1 and PROMISE 2 phase 3 clinical trials for eptinezumab, their lead investigational product for migraine prevention, at the American Headache Society annual meeting. The data highlights eptinezumab's efficacy in reducing migraine days and improving quality of life for patients.